Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC2R | Q01718 | 12/20 | 0.52 |
| ▸ | ACP1 | P24666 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.37 |
| ▸ | PDE1A | P54750 | 2/20 | 0.37 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.37 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21700767 | 0.85 | MC2R (0.63) | MC2RACP1PDE1B | |
| SCHEMBL31188914 | 0.85 | MC2R (0.63) | MC2RACP1PDE1B | |
| SCHEMBL21700754 | 0.84 | MC2R (0.68) | MC2RACP1PDE1APDE1BPDE1C | |
| SCHEMBL21700582 | 0.83 | MC2R (0.61) | MC2RACP1 | |
| Trifluoroacetic Acid SCHEMBL21700916 | 0.81 | MC2R (0.48) | MC2RACP1PDE1APDE1BPDE1C | |
| SCHEMBL29963742 | 0.81 | MC2R (0.56) | MC2R | |
| SCHEMBL30649176 | 0.81 | MC2R (0.43) | MC2RACP1PDE1APDE1BPDE1C | |
| SCHEMBL21700773 | 0.81 | MC2R (0.43) | MC2RACP1PDE1APDE1BPDE1C | |
| SCHEMBL21700836 | 0.81 | MC2R (0.43) | MC2RACP1CHRNA7PDE1APDE1B | |
| SCHEMBL31188906 | 0.81 | MC2R (0.43) | MC2RACP1CHRNA7PDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479825-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20230015914-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-01-19 | — | — | US | disclosed |
| EP-4054583-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479825-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | MC2R 3/4885ACP1 3274/4885CHRNA7 295/4885 |
| US-20230015914-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | MC2R 3/4885ACP1 3274/4885CHRNA7 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.